RBC Capital Remains Buyers of Karyopharm Therapeutics (KPTI) Following 8% Gain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 0.09 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.09 | 52 Week High | $19.41 | |||
| Open | $0.09 | 52 Week Low | $4.83 | |||
| Day High | $0.09 | P/E | N/A | |||
| Day Low | $0.09 | EPS | $-2.74 | |||
| Volume | 107,521 | |||||
